| 2.51 0.015 (0.6%) | 06-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.35 | 1-year : | 3.91 |
| Resists | First : | 2.86 | Second : | 3.35 |
| Pivot price | 2.6  |
|||
| Supports | First : | 2.37 | Second : | 2.06 |
| MAs | MA(5) : | 2.52 |
MA(20) : | 2.6 |
| MA(100) : | 2.4 |
MA(250) : | 2.81 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 28.6  |
D(3) : | 25.5 |
| RSI | RSI(14): 49 |
|||
| 52-week | High : | 4.19 | Low : | 1.87 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ LSTA ] has closed above bottom band by 18.2%. Bollinger Bands are 54.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.65 - 2.67 | 2.67 - 2.69 |
| Low: | 2.41 - 2.43 | 2.43 - 2.44 |
| Close: | 2.49 - 2.51 | 2.51 - 2.54 |
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Wed, 11 Jun 2025
Lisata Therapeutics to Present at the 2025 BIO International Convention | LSTA Stock News - GuruFocus
Wed, 11 Jun 2025
Lisata Therapeutics to Present at the 2025 BIO International Convention - GlobeNewswire
Wed, 11 Jun 2025
Lisata CEO to Reveal Latest Cancer Treatment Developments at Major Biotech Conference - Stock Titan
Wed, 11 Jun 2025
Lisata Therapeutics CEO to present at 2025 BIO International Convention - Proactive financial news
Fri, 09 May 2025
Lisata Therapeutics Inc (LSTA) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Market ... - Yahoo Finance
Thu, 08 May 2025
Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 7.1e+006 (%) |
| Held by Institutions | 20.1 (%) |
| Shares Short | 29 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.148e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 165.5 % |
| Return on Equity (ttm) | -35.1 % |
| Qtrly Rev. Growth | 1e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -56.92 |
| EBITDA (p.s.) | 1e+006 |
| Qtrly Earnings Growth | -2.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 0.85 |
| Dividend | 0 |
| Forward Dividend | 23620 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|